Effects of Minimally Invasive Gynecologic Surgery Subspecialty Training on Outcomes of Hysterectomy for Benign Indications.

Raanan Meyer, Rebecca Schneyer, Kacey Hamilton, Gabriel Levin, Mireille D Truong, Matthew T Siedhoff, Kelly N Wright

Abstract read

In one paragraph

Article in O&G open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Raanan MeyerDivision of Minimally Invasive Gynecologic Surgery, Department of Obstetrics and Gynecology, Cedars Sinai Medical Center, Los Angeles, California; The Dr. Pinchas Bornstein Talpiot Medical Leadership Program, Sheba Medical Center, Tel Hashomer, Ramat-Gan, and the Department of Gynecologic Oncology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel; and the Lady Davis Institute for Cancer Research, Jewish General Hospital, McGill University, Quebec, Canada.

Rebecca SchneyerDivision of Minimally Invasive Gynecologic Surgery, Department of Obstetrics and Gynecology, Cedars Sinai Medical Center, Los Angeles, California; The Dr. Pinchas Bornstein Talpiot Medical Leadership Program, Sheba Medical Center, Tel Hashomer, Ramat-Gan, and the Department of Gynecologic Oncology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel; and the Lady Davis Institute for Cancer Research, Jewish General Hospital, McGill University, Quebec, Canada.

Kacey HamiltonDivision of Minimally Invasive Gynecologic Surgery, Department of Obstetrics and Gynecology, Cedars Sinai Medical Center, Los Angeles, California; The Dr. Pinchas Bornstein Talpiot Medical Leadership Program, Sheba Medical Center, Tel Hashomer, Ramat-Gan, and the Department of Gynecologic Oncology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel; and the Lady Davis Institute for Cancer Research, Jewish General Hospital, McGill University, Quebec, Canada.

Gabriel LevinDivision of Minimally Invasive Gynecologic Surgery, Department of Obstetrics and Gynecology, Cedars Sinai Medical Center, Los Angeles, California; The Dr. Pinchas Bornstein Talpiot Medical Leadership Program, Sheba Medical Center, Tel Hashomer, Ramat-Gan, and the Department of Gynecologic Oncology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel; and the Lady Davis Institute for Cancer Research, Jewish General Hospital, McGill University, Quebec, Canada.

Mireille D TruongDivision of Minimally Invasive Gynecologic Surgery, Department of Obstetrics and Gynecology, Cedars Sinai Medical Center, Los Angeles, California; The Dr. Pinchas Bornstein Talpiot Medical Leadership Program, Sheba Medical Center, Tel Hashomer, Ramat-Gan, and the Department of Gynecologic Oncology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel; and the Lady Davis Institute for Cancer Research, Jewish General Hospital, McGill University, Quebec, Canada.

Matthew T SiedhoffDivision of Minimally Invasive Gynecologic Surgery, Department of Obstetrics and Gynecology, Cedars Sinai Medical Center, Los Angeles, California; The Dr. Pinchas Bornstein Talpiot Medical Leadership Program, Sheba Medical Center, Tel Hashomer, Ramat-Gan, and the Department of Gynecologic Oncology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel; and the Lady Davis Institute for Cancer Research, Jewish General Hospital, McGill University, Quebec, Canada.

Kelly N WrightDivision of Minimally Invasive Gynecologic Surgery, Department of Obstetrics and Gynecology, Cedars Sinai Medical Center, Los Angeles, California; The Dr. Pinchas Bornstein Talpiot Medical Leadership Program, Sheba Medical Center, Tel Hashomer, Ramat-Gan, and the Department of Gynecologic Oncology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel; and the Lady Davis Institute for Cancer Research, Jewish General Hospital, McGill University, Quebec, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo compare surgical outcomes among patients undergoing hysterectomy for benign indications with minimally invasive gynecologic surgery subspecialists (MIGS group), gynecologic oncologists (GO group), and general obstetrician-gynecologists (OB-GYN group).

methodsWe conducted a retrospective cohort study from a quaternary care academic hospital. We included patients undergoing hysterectomy for benign reasons from 2015 to 2020. Exclusion criteria were malignant, premalignant, or suspected malignant condition, pelvic mass (other than leiomyoma), concomitant correction of pelvic organ prolapse, and peripartum hysterectomy. The primary outcome was the odds of a composite of any intraoperative or postoperative complications by surgeon group. Secondary outcomes were conversion to laparotomy, estimated blood loss, and admission times by surgeon subspecialty.

resultsA total of 946 hysterectomies were performed during the study period, of which 356 (37.6%) were performed by obstetrician-gynecologists (ob-gyns), 220 (23.3%) by gynecologic oncologists, and 370 (39.1%) by minimally invasive gynecologic surgeons. Abdominal hysterectomies were performed in 36.8% of cases in the OB-GYN group and 30.0% of cases in the GO group, compared with 0.3% of cases in the MIGS group (

conclusionFellowship-trained minimally invasive gynecologic surgery subspecialists had lower rates of perioperative complications for hysterectomy for benign indications compared with gynecologic oncologists and ob-gyns. Minimally invasive gynecologic surgery cases were also associated with fewer rates of laparotomy, less blood loss, and shorter hospital stays.

Identifiers

PMID41001602

DOI10.1097/og9.0000000000000045

PMCPMC12456584

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.